Cedar clinical research, by numinus, the top enrolling clinical research site for mindmed's phase 2b study evaluating mm-120

Vancouver, bc , june 5, 2023 /prnewswire/ - numinus wellness inc. ("numinus" or the "company") (tsx: numi) (otcqx: numif), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce cedar clinical research (ccr) is a top research site for mindmed's phase 2b study evaluating mm-120 (lysergide d-tartrate) for general anxiety disorder.  ccr's research clinic in draper, utah, is the top enrolling site for the research study – having enrolled and dosed 19 clinical trial participants for the study to date.
MNMD Ratings Summary
MNMD Quant Ranking